Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

CRISPR Therapeutics CRSP is expected to report fourth ... development of two next-generation CAR-T therapy candidates — CTX112 (targeting CD19-positive B-cell malignancies) and CTX131 (targeting ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

CRISPR Therapeutics is the gene-editing specialist ... designation to CRISPR's CTX112, an investigational treatment for certain B-cell malignancies. This designation is reserved for therapies ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ... The FDA has designated the company’s CTX112 as a regenerative medicine advanced therapy (RMAT), and ...

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO ... the RMAT designation from the FDA for CTX112 in oncology. And so we’re going to have ...

CRISPR Therapeutics AG (NASDAQ ... The FDA has designated the company’s CTX112 as a regenerative medicine advanced therapy (RMAT), and CTX131 is currently undergoing clinical trials.